30 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
38
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
Pfizer
15
Organic anion transporter 3 interacts selectively with lipophilicß-lactam antibiotics.
Wilkes University
1
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
Nippon Boehringer Ingelheim
8
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
Kyorin University
8
Interaction of human organic anion transporters with various cephalosporin antibiotics.
Kyorin University
4
Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters.
Kyorin University
4
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions.
University of Tokyo
4
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
The University of Tokyo
1
Interactions of human organic anion as well as cation transporters with indoxyl sulfate.
Nagoya University School of Medicine
1
Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.
Georg-August-Universit£T
2
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
Kyoto University Hospital
5
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
Kyorin University
2
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Novartis Pharma
13
Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948.
Pfizer Inc.
2
The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075.
Aligos Belgium BV
27
Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.
Jacobio Pharmaceuticals
13
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
Pfizer
30
Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.
Bristol Myers Squibb
56
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.
Bristol Myers Squibb
1
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
Hemoshear Therapeutics
61
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
TBA
9
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Pfizer
17
Pharmacological urate-lowering approaches in chronic kidney disease.
West China Hospital of Sichuan University
8
Dihydrophenanthrenes from Juncus effusus as Inhibitors of OAT1 and OAT3.
Tianjin University
9
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
Kyorin University School of Medicine
5
Characterization of ochratoxin A transport by human organic anion transporters.
Kyorin University
5
Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.
University of Tokyo
2
Characterization of uremic toxin transport by organic anion transporters in the kidney.
University of Tokyo
4
SERIES OF PIPERIDINE-SUBSTITUTED BENZOIC ACID COMPOUNDS, AND USE THEREOF
Medshine Discovery